Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3zeta)

Mfr.No.	78655
Description	The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. The lentiviruses also transduce a puromycin selection gene. B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma. The lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM.
Applications Range	Positive control for anti-BCMA CAR evaluation in T cells Transduction optimization studies
Storage	Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.
Shipping	-80°C